AEA, MRGE, TSRX - CRWESelect.com Stock News! Advance America, Merge Healthcare, Trius Therapeutics (Video Included Inside)

FOR IMMEDIATE RELEASE
Las Vegas, Nevada, United States of America (Free-Press-Release.com) February 16, 2012 -- To view video, and read the full article visit URL http://crweselect.com/28631/stock-alerts/aea-mrge-tsrx-crweselectcom-stock-news-advance-america-merge-healthcare-trius-therapeutics-video-included-inside/

Advance America, Cash Advance Centers, Inc. (NYSE: AEA)

Advance America, Cash Advance Centers, Inc. (AEA) and Grupo Elektra, S.A.B. de C.V. announced that Advance America and subsidiaries of Grupo Elektra have entered into a definitive agreement under which Grupo Elektra will acquire control of all of the outstanding shares of Advance America, a leading U.S. short-term lender, for $10.50 per share in cash, representing a 32.7% premium to the Company's closing price of $7.91 on February 15, 2012 . The total transaction value is approximately $780 million, including the Company's outstanding debt as of December 31, 2011.

Founded in 1997, AEA is the leading provider of non-bank cash advance services in the United States, with approximately 2,600 centers in 29 states, the United Kingdom, and Canada. Advance America offers convenient, less-costly credit options to consumers whose needs are not met by traditional financial institutions. Advance America is a founding member of the Community Financial Services Association of America (CFSA), whose mission is to promote laws that provide substantive consumer protections and to encourage responsible industry practices.

For more information about AEA please visit http://www.advanceamerica.net

****

Merge Healthcare Incorporated. (NASDAQ: MRGE)

Merge Healthcare Incorporated. (MRGE) announced its financial and business results for the fourth quarter and full year of 2011. Financial highlights included that the Company's revenue grew to $64.1 million ($65.1 million on a pro forma basis) in the quarter, compared to $46.2 million ($51.1 million on a pro forma basis) in the fourth quarter of 2010 - an increase of 39%.

MRGE is a leading provider of enterprise imaging and interoperability solutions. Merge solutions facilitate the sharing of images to create a more effective and efficient electronic healthcare experience for patients and physicians. Merge provides enterprise imaging solutions for radiology, cardiology, orthopaedics and eye care; a suite of products for clinical trials; software for financial and pre-surgical management, and applications that fuel the largest modality vendors in the world. Merge's products have been used by healthcare providers, vendors and researchers worldwide to improve patient care for more than 20 years.

For more information about MRGE please visit http://www.merge.com

****

Trius Therapeutics, Inc. (NASDAQ: TSRX)

Trius Therapeutics, Inc. (TSRX) announced the issuance of Patent # 908206 by the State Intellectual Property Office of the People's Republic of China (PRC) that protects the composition of matter of the Company's Phase 3 investigational drug, tedizolid phosphate, through 2024. In addition to the issuance in China, patents for tedizolid phosphate have also issued in other jurisdictions including Australia, Canada, Europe, India, Japan, Mexico, Russia and the United States.

TSRX is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. The company's lead investigational drug, tedizolid phosphate, is a once daily, IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of ABSSSI. Trius has two Special Protocol Assessments with the FDA for its two Phase 3 ABSSSI trials and has partnered with Bayer HealthCare for the development and commercialization of tedizolid phosphate outside of the U.S., Canada and the European Union. In addition to the company's tedizolid phosphate clinical program, Trius has initiated IND-enabling studies for its Gyrase-B development candidate with potent activity against Gram-negative bacterial pathogens including multi-drug resistant strains of E. coli, Klebsiella, Acinetobacter and Pseudomonas. The Gyrase-B program is one of the three preclinical programs fully supported by federal contracts.

For more information about TSRX please visit http://www.triusrx.com

To read the full article visit URL http://crweselect.com/28631/stock-alerts/aea-mrge-tsrx-crweselectcom-stock-news-advance-america-merge-healthcare-trius-therapeutics-video-included-inside/

**********************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

AEAcrweselect0216
MRGEcrweselect0216
TSRXcrweselect0216

Advance America     AEA     Grupo Elektra     Merge Healthcare     MRGE     select     Trius Therapeutics     TSRX